HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rexall Showcase International

This article was originally published in The Tan Sheet

Executive Summary

Rexall's direct sales subsidiary voluntarily dismisses its complaint against the Florida Attorney General's office May 22. RSI filed a lawsuit hoping to prevent the AG from forcing the company to turn over a variety of documents related to an ongoing pyramid scheme investigation (1"The Tan Sheet" April 3, p. 10). Rexall had argued the information was protected by trade secret laws, but canceled the scheduled hearing and will turn over all relevant papers. The AG says the company reserves the right to object to any future request for documents

You may also be interested in...



Rexall Showcase Challenging Florida AG Over Trade Secret Disclosure

Rexall Sundown's direct sales division, Rexall Showcase International, has filed suit against the state of Florida to protect the confidentiality of trade secrets it believes will be made public during a probe of the company's business practices.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133033

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel